153 related articles for article (PubMed ID: 8881897)
1. Clinical aspects: preliminary experience with a novel oral formulation of cyclosporin (Neoral).
Berth-Jones J
Br J Dermatol; 1996 Sep; 135 Suppl 48():5-8. PubMed ID: 8881897
[TBL] [Abstract][Full Text] [Related]
2. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses.
Bourke JF; Berth-Jones J; Holder J; Graham-Brown RA
Br J Dermatol; 1996 Apr; 134(4):777-9. PubMed ID: 8733391
[TBL] [Abstract][Full Text] [Related]
3. Neoral (cyclosporin) in dermatology: technical aspects.
Smith SG
Br J Dermatol; 1996 Sep; 135 Suppl 48():2-4. PubMed ID: 8881896
[TBL] [Abstract][Full Text] [Related]
4. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
[TBL] [Abstract][Full Text] [Related]
5. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
[TBL] [Abstract][Full Text] [Related]
6. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis.
Chawla M; Ali M; Marks R
Br J Dermatol; 1996 Sep; 135 Suppl 48():9-14. PubMed ID: 8881898
[TBL] [Abstract][Full Text] [Related]
8. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
[TBL] [Abstract][Full Text] [Related]
9. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
Salek MS; Finlay AY; Lewis JJ; Sumner MI
Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
Koo J
Br J Dermatol; 1998 Jul; 139(1):88-95. PubMed ID: 9764154
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporin in childhood psoriasis.
Perrett CM; Ilchyshyn A; Berth-Jones J
J Dermatolog Treat; 2003 Jun; 14(2):113-8. PubMed ID: 12775319
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
Noble S; Markham A
Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
[TBL] [Abstract][Full Text] [Related]
14. Comparative tolerability of systemic treatments for plaque-type psoriasis.
McClure SL; Valentine J; Gordon KB
Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213
[TBL] [Abstract][Full Text] [Related]
15. Individualized short-course cyclosporin therapy in psoriasis.
Finzi AF
Br J Dermatol; 1996 Sep; 135 Suppl 48():31-4. PubMed ID: 8881902
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.
Hakkaart-van Roijen L; Verboom P; Redekop WK; Touw KR; Rutten FF
Pharmacoeconomics; 2001; 19(5 Pt 2):599-608. PubMed ID: 11465304
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis.
Erkko P; Granlund H; Nuutinen M; Reitamo S
Br J Dermatol; 1997 Jan; 136(1):82-8. PubMed ID: 9039300
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancy associated with cyclosporin use in psoriasis.
Paul C; Hornig F
Dermatology; 1999; 198(3):320-1. PubMed ID: 10419287
[No Abstract] [Full Text] [Related]
19. Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis.
De Silva BD; Benton EC; Tidman MJ
Clin Exp Dermatol; 1999 Jan; 24(1):10-3. PubMed ID: 10233640
[TBL] [Abstract][Full Text] [Related]
20. Advances in psoriasis therapy.
Koo J; Nguyen Q; Gambla C
Adv Dermatol; 1997; 12():47-72; discussion 73. PubMed ID: 8973735
[No Abstract] [Full Text] [Related]
[Next] [New Search]
